###begin article-title 0
###xml 36 41 <span type="species:ncbi:9606">Human</span>
Reassessing the Role of APOBEC3G in Human Immunodeficiency Virus Type 1 Infection of Quiescent CD4+ T-Cells
###end article-title 0
###begin p 1
Conceived and designed the experiments: MK ISYC. Performed the experiments: MK YN. Analyzed the data: MK. Wrote the paper: MK ISYC.
###end p 1
###begin p 2
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 718 723 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1026 1031 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 1112 1117 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 is restricted for infection of primary quiescent T-cells. After viral entry, reverse transcription is initiated but is not completed. Various hypotheses have been proposed for this cellular restriction including insufficient nucleotide pools and cellular factors, but none have been confirmed as the primary mechanism for restriction. A recent study by Chiu et al. implicates APOBEC3G, an anti-retroviral cytidine deaminase, as the cellular restriction factor. Here, we attempted to confirm these findings using the same strategy as reported by Chiu et al. of siRNA targeting knock-down of APOBEC3G expression. In contrast to the published study, our results do not support a role for APOBEC3G in restriction of HIV-1 in quiescent CD4+ T-cells. In our study, we tested the same siRNA as reported by Chiu et al. as well as two additional siRNAs targeting APOBEC3G, one of which showed 2-fold greater knock-down of APOBEC3G mRNA. However, none of the three siRNAs tested had a discernable effect on enhancing infection by HIV-1 in quiescent CD4+ T-cells. Therefore, we conclude that the primary mechanism of HIV-1 restriction in quiescent CD4+ T-cells remains to be elucidated.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 84 89 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 732 737 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 917 922 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 985 990 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In 1990, we demonstrated that unstimulated quiescent T-lymphocytes are resistant to HIV-1 infection. Viruses can get into the cell, and reverse transcription is started, but it is not completed. Various hypotheses have been proposed for this blockage including insufficient free nucleotides and inhibiting cellular factors, but none have been confirmed as the primary mechanism for this blockage. A recent study by Chiu et al. provided one possible mechanism for the blockage in quiescent T-lymphocytes: APOBEC3G, an anti-retroviral cytidine deaminase that was implicated as the responsible factor for this blockage. We have attempted to confirm these findings using published methods. Chiu et al. reported a 37-fold enhancement of HIV-1 infection in quiescent T-lymphocytes by decreasing the levels of APOBEC3G. In contrast to the published study, our results do not support a role for APOBEC3G in the inhibition of HIV-1 infection in quiescent T-lymphocytes. We believe the block of HIV-1 infection of quiescent T-cells remains unknown.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 171 174 171 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zhou1">[1]</xref>
###xml 175 178 175 178 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zack1">[5]</xref>
###xml 206 209 206 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Unutmaz1">[6]</xref>
###xml 278 279 278 279 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sub>
###xml 284 286 284 286 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1a</sub>
###xml 361 363 361 363 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1b</sub>
###xml 450 453 450 453 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Darzynkiewicz1">[7]</xref>
###xml 561 564 561 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Korin1">[8]</xref>
###xml 565 568 565 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Korin2">[9]</xref>
###xml 771 774 771 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zack1">[5]</xref>
###xml 775 779 775 779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Vatakis1">[10]</xref>
###xml 780 784 780 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zack2">[11]</xref>
###xml 1006 1010 1006 1010 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Yamashita1">[12]</xref>
###xml 1011 1015 1011 1015 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Goff1">[13]</xref>
###xml 1034 1038 1034 1038 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Ganesh1">[14]</xref>
###xml 1066 1070 1066 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 76 111 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
###xml 113 118 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 326 331 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 598 603 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 939 944 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Nonproliferating quiescent CD4+ T-cells are resistant to the infection with human immunodeficiency virus type 1 (HIV-1) unless they are activated by mitogenic stimulation [1]-[5] or by cytokine stimulation [6]. Other studies demonstrated that quiescent T-cells at the stage of G0 or G1a of the cell cycle are nonpermissive to HIV-1 infection, but cells in the G1b phase of the cell cycle which show high levels of RNA synthesis, but no DNA synthesis [7] are permissive, and the induction of cell cycle progression per se is not needed to render cell permissive [8],[9]. Earlier studies showed that HIV-1 infection in quiescent CD4+ T-cells results in 4-fold lower levels of viral entry, and incomplete reverse transcription and minimum levels of integration are observed [5],[10],[11]. Although the precise mechanisms involved in this blockage remain unidentified, a number of cellular factors have been reported as restriction factors to HIV-1 infection in quiescent CD4+ T-cells (reviewed in more detail [12],[13]), including Murr1 [14] and most recently APOBEC3G [15].
###end p 6
###begin p 7
###xml 117 121 117 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-GoilaGaur1">[16]</xref>
###xml 122 126 122 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zhang1">[20]</xref>
###xml 390 394 390 394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-GoilaGaur1">[16]</xref>
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu2">[21]</xref>
###xml 536 540 536 540 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Marin1">[22]</xref>
###xml 541 545 541 545 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Stopak1">[24]</xref>
###xml 616 620 616 620 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 621 625 621 625 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Bogerd1">[25]</xref>
###xml 626 630 626 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Nguyen1">[26]</xref>
###xml 111 116 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 143 148 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 406 411 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G is a cytidine deaminase and has well characterized potent anti-retroviral activity, including against HIV-1 [16]-[20]. In the case of HIV-1, it acts through incorporation into virions where it edits newly synthesized viral DNA in the next infection cycle by deaminating dC to dU, resulting in lethal G-to-A hypermutations in the single stranded viral DNA intermediate (reviewed in [16],[21]). The HIV-1 encoded viral infectivity factor (Vif) counteracts the effects of virion incorporated APOBEC3G by mediating its degradation [22]-[24]. A deaminase-independent anti-viral activity has also been identified [15],[25],[26] but the detailed mechanism of action is poorly understood.
###end p 7
###begin p 8
###xml 558 563 558 563 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240WT</sub>
###xml 83 88 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 238 243 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 764 769 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 865 870 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Using siRNA mediated knock-down, Chiu et al. concluded that APOBEC3G plays role in HIV-1 restriction in quiescent resting CD4+ T-cells. In those cells, APOBEC3G exists as a low molecular-mass (LMM) ribonucleoprotein complex that inhibits HIV-1 infection prior to reverse transcription probably through its RNA binding activity. In this report, we attempted to reproduce the findings using the identical strategy of siRNA mediated knock-down of APOBEC3G expression as reported by Chiu et al. By nucleofection of the same siRNA as reported by Chiu et al (siA3G240WT) as well as two additional siRNAs targeting APOBEC3G, we confirm reduction in APOBEC3G mRNA and protein in quiescent CD4+ T-cells. However, none of the siRNAs resulted in a significant enhancement of HIV-1 infection in those cells. Therefore, we conclude that the role of APOBEC3G in the mechanism of HIV-1 restriction in quiescent CD4+ T-cells is unclear.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
Synthesized siRNAs can transduce into quiescent CD4+ T-cells with high efficiency by nucleofection
###end title 10
###begin p 11
###xml 270 274 270 274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 358 364 358 364 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 423 427 423 427 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-He1">[27]</xref>
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chiu et al. reported a 37-fold enhancement of HIV-1 infection by an HSA bearing reporter virus in unstimulated quiescent CD4+ T-cells following nucleofection of siRNA directed to APOBEC3G - a level that is nearly comparable to that observed in PHA/IL-2 stimulated cells [15]. We mimicked the experimental conditions of Chiu et al. using the same siRNA (siA3G240 WT) and VSV-G pseudotyped HSA reporter virus (NL4-3 HSA R-E- [27]).
###end p 11
###begin p 12
###xml 134 135 134 135 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 499 503 495 499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 517 526 513 522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g001">Figure 1A</xref>
###xml 917 926 913 922 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g001">Figure 1B</xref>
###xml 981 990 977 986 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g001">Figure 1B</xref>
We first tested the efficiency of nucleofection using fluorescein isothiocyanate (FITC) conjugated siRNA. Quiescent CD4+ T-cells (5x106) were nucleofected with 2 microg of siRNA following the manufacturer's protocol and the efficiency of siRNA transduction monitored by flow cytometry. We consistently observed 5-20% higher mortality between nucleofected cells compared to untreated control cells 48 hr after nucleofection. This level was similar or slightly lower than that reported by Chiu et al. [15]. As shown in Figure 1A, FITC-conjugated siRNA was nucleofected into nearly 100% of the cells from two independent blood donors. We further tested whether the RNAi mechanism is functional in quiescent CD4+ T-cells using siRNA specific to the CD4 molecule. After nucleofection, the cell surface expression of CD4 molecules on quiescent CD4+ T-cells decreased 3-fold as measured by mean fluorescent intensity (MFI) (Figure 1B, siCD4) compared to control siRNA nucleofected cells (Figure 1B, siControl). Identical results were also observed using cells from another independent donor (data not shown).
###end p 12
###begin title 13
siRNAs can transduce into quiescent CD4+ T-cells with high efficiency by nucleofection.
###end title 13
###begin p 14
###xml 172 175 172 175 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
(A) Quiescent CD4+ T-cells were purified from freshly isolated PBMCs of two independent donors with CD4 magnetic beads and nucleofected with siRNA targeting APOBEC3G (siA3G883), conjugated with (FITC) or without FITC (None). Cells were analyzed by flow cytometry 3 hr after nucleofection. (B) To monitor the integrity of the RNAi machinery, quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNA targeting CD4 (siCD4), control siRNA (siControl), or no siRNA (None). The levels of cell surface CD4 expression were monitored by flow cytometry using PE-conjugated anti-CD4 antibody or isotype-matched control 48 hr after nucleofection and represented by mean fluorescent intensity (MFI) in each panel. The solid line represents PE-CD4 antibody stained cells, whereas the shaded area represents isotype control staining.
###end p 14
###begin title 15
The expression of APOBEC3G effectively knock-down by nucleofection of siRNA directed to the sequence of APOBEC3G in quiescent CD4+ T-cells
###end title 15
###begin p 16
###xml 125 130 125 130 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240WT</sub>
###xml 202 206 202 206 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Pion1">[28]</xref>
###xml 292 295 292 295 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 305 308 305 308 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 468 471 468 471 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 473 482 473 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g002">Figure 2A</xref>
###xml 585 594 585 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g002">Figure 2B</xref>
###xml 882 888 882 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 895 898 895 898 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 909 912 909 912 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 988 992 988 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
We next examined that the levels of knocking-down of APOBEC3G by siRNA reported by Chiu et al., that targeted APOBEC3G (siA3G240WT). We also tested two additional siRNAs, one previously published siRNA [28] and another identified by ourselves directed to distinct sequences of APOBEC3G (siA3G726 and siA3G883, respectively). These siRNAs gave greater downregulation of APOBEC3G mRNA than that reported by Chiu et al.; 6-fold reduction was observed in the case of siA3G883 (Figure 2A). We further examined the protein levels of APOBEC3G in siRNA nucleofected cells by Western blotting (Figure 2B). All three siRNAs targeting APOBEC3G showed comparable levels of reduction of APOBEC3G protein at 48 hr after nucleofection; the band intensities of the cells nucleofected with siRNA targeting APOBEC3G compared to that of control siRNA nucleofected cells were 35%, 33%, and 31% by siA3G240 WT, siA3G726, and siA3G883, respectively, a decrease in levels similar to that reported by Chiu et al [15].
###end p 16
###begin title 17
siRNAs directed to the sequence of APOBEC3G effectively knock-down the expression of APOBEC3G in quiescent CD4+ T-cells.
###end title 17
###begin p 18
###xml 247 251 244 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Jin1">[31]</xref>
###xml 314 320 311 317 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 337 340 334 337 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 357 360 354 357 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
(A) Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for two days. Total RNA was isolated, and the levels of APOBEC3G mRNA were monitored by quantitative real time RT-PCR using beta-actin as an internal control [31]. P values (asterisks) versus control siRNA were 0.00022 (siA3G240 WT), 0.00013 (siA3G726), 0.00005 (siA3G883), respectively. (B) Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for two days. Cells were lysed in 0.5% SDS, and the levels of APOBEC3G protein were monitored by Western blotting. beta-actin was used as a loading control.
###end p 18
###begin title 19
APOBEC3G knock-down in quiescent CD4+ T-cells does not affect HSA reporter virus infection
###end title 19
###begin p 20
###xml 82 88 82 88 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 95 98 95 98 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 121 124 121 124 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 146 152 146 152 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 MT</sub>
###xml 218 226 218 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g003">Figure 3</xref>
###xml 682 690 682 690 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g003">Figure 3</xref>
###xml 697 703 697 703 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 817 825 817 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g002">Figure 2</xref>
###xml 946 955 946 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g003">Figures 3</xref>
###xml 960 961 960 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g004">4</xref>
###xml 968 971 968 971 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 983 991 983 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 998 1001 998 1001 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 1011 1014 1011 1014 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 1460 1461 1460 1461 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 1469 1477 1469 1477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g004">Figure 4</xref>
###xml 1618 1626 1618 1626 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g004">Figure 4</xref>
###xml 1633 1639 1633 1639 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 1649 1652 1649 1652 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 1672 1680 1672 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g004">Figure 4</xref>
###xml 1901 1905 1901 1905 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 2011 2030 2011 2030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000342.s001">Figures S1A and S1B</xref>
###xml 2224 2228 2224 2228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 2254 2258 <span type="species:ncbi:9913">calf</span>
###xml 2286 2291 <span type="species:ncbi:9606">human</span>
Using above described protocol, we nucleofected siRNAs targeted to APOBEC3G [siA3G240 WT, siA3G726 (see below), and siA3G883] or the mutant (siA3G240 MT) and non-specific siRNA (siControl) into quiescent CD4+ T-cells (Figure 3). The cells were then infected by an NL4-3 HSA reporter virus at 2 day post-nucleofection. As expected, CD4+ T-cells stimulated with PHA/IL-2 were highly susceptible to infection by the HSA reporter virus and the virus infection was strongly diminished in the presence of AZT. In striking contrast to Chiu et al., we did not observe any enhancement of HSA expression in quiescent CD4+ T-cells in the presence of siRNA to APOBEC3G reported by Chiu et al. (Figure 3, siA3G240 WT). We further tested two additional siRNAs that were more efficient at decreasing APOBEC3G expression as shown in Figure 2. However, there was no discernable effect by these new siRNAs targeting APOBEC3G on enhancing reporter virus infection (Figures 3 and 4, siA3G883 are shown; Figure 5, siA3G726 and siA3G883 are shown). We repeated the experiment using quiescent CD4+ T-cells from 6 different donors and in all cases, we did not observe enhancement of the levels of the HSA expression after nucleofection of APOBEC3G specific siRNA (data not shown). We further tested infection with three different amounts of NL4-3 virus carrying the EGFP reporter rather than the HSA reporter. The infection efficiency reached maximal level with 125 ng of p24 per 1x105 cells (Figure 4). However, we did not observe any significant differences in EGFP expression between the cells nucleofected with siRNAs targeting APOBEC3G (Figure 4, siA3G240 WT and siA3G883) or control siRNA (Figure 4, siControl) even with the higher amounts of virus (250 ng and 500 ng of p24). Chiu et al. also reported that the knock-down of APOBEC3G by siRNA in quiescent CD4+ T-cells continued for at least 88 hr after nucleofection [15]. Therefore, we examined infection with the same EGFP reporter virus at 72 and 96 hr after nucleofection (Figures S1A and S1B, respectively). However, we did not observe any effect of APOBEC3G siRNA transduction on EGFP expression at those time points. Furthermore, we tested the same culture medium used by Chiu et al.[15] that contained 10% fetal calf serum (FCS) instead of 10% human serum, but neither culture condition showed any enhancement of reporter virus infection in quiescent CD4+ T-cells (data not shown). Thus, our results obtained under similar conditions were discrepant with those of Chiu et al.
###end p 20
###begin title 21
###xml 73 78 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
siRNA mediated knock-down of APOBEC3G does not affect the infectivity of HIV-1 reporter virus.
###end title 21
###begin p 22
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for two days. Cells were then infected with VSV-G pseudotyped NL4-3 HSA reporter virus (125 ng of p24 per 1x105 cells) for 3 hr and subsequently cultured in the absence or presence of 25 microM AZT. Expression of HSA was monitored 48 hr after the reporter virus infection by flow cytometry using PE-conjugated anti-HSA antibody. Unstimulated non-nucleofected cells (Unstimulated) and unstimulated cells nucleofected with control siRNA (siControl) served as negative controls. Cells stimulated with PHA (5 microg/ml) and IL-2 (20 U/ml) served as positive controls (Stimulated). Comparable results were obtained using cells from six different donors.
###end p 22
###begin title 23
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The infectivity of HIV-1 reporter virus on APOBEC3G knocked-down quiescent CD4+ T-cells is not affected by virus multiplicity of infection.
###end title 23
###begin p 24
###xml 111 121 111 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000342.s001">Figure S1A</xref>
###xml 138 148 138 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000342.s001">Figure S1B</xref>
###xml 294 295 294 295 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for two days, three days (Figure S1A), or four days (Figure S1B). Cells were subsequently infected with VSV-G pseudotyped NL4-3 EGFP reporter virus at three different MOIs (125, 250, and 500 ng of p24 per 1x105 cells) for 3 hr, and cultured in the absence or presence of 25 microM AZT. Expression of EGFP was monitored 48 hr after infection by flow cytometry. Unstimulated non-nucleofected cells (Unstimulated) and unstimulated cells nucleofected with control siRNA (siControl) or buffer only (buffer) served as negative controls. Cells stimulated with PHA (5 microg/ml) and IL-2 (20 U/ml) served as positive controls (Stimulated). Comparable results were obtained using cells from four different donors.
###end p 24
###begin title 25
Knock-down of APOBEC3G does not affect the entry of the reporter viruses into quiescent CD4+ T-cells.
###end title 25
###begin p 26
###xml 196 197 196 197 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for two days. Cells were then infected with VSV-G-pseudotyped NL4-3 EGFP reporter virus (125 ng of p24 per 1x105 cells) for 3 hr. After infection, half of the cells were stimulated with PHA (5 microg/ml) and IL-2 (20 U/ml) (Stim), and the other half of the cells were cultured without stimulation (-). Expression of EGFP was monitored 48 hr after infection by flow cytometry. Unstimulated non-nucleofected cells (Unstimulated) and unstimulated cells nucleofected with control siRNA (siControl) served as negative controls. Cells stimulated with PHA (5 microg/ml) and IL-2 (20 U/ml) served as positive controls (Stimulated). Comparable results were obtained using cells from three different donors. Heat-inactivated (HI) viruses were used as negative controls for virus infection.
###end p 26
###begin title 27
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Knock-down of APOBEC3G does not interfere with HIV-1 entry into quiescent CD4+ T-cells
###end title 27
###begin p 28
###xml 539 548 539 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000342.s002">Figure S2</xref>
###xml 582 591 582 591 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g003">Figures 3</xref>
###xml 596 597 596 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g004">4</xref>
###xml 717 725 717 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 732 738 732 738 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 747 750 747 750 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 762 765 762 765 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 856 864 856 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 871 877 871 877 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 889 892 889 892 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 907 910 907 910 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 1005 1013 1005 1013 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 1064 1072 1064 1072 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 1095 1101 1095 1101 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 1113 1116 1113 1116 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 1132 1135 1132 1135 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 1249 1257 1249 1257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 1264 1270 1264 1270 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 1289 1292 1289 1292 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 1315 1318 1315 1318 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 1348 1356 1348 1356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 1363 1366 1363 1366 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240</sub>
###xml 1366 1368 1366 1368 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MT</sub>
###xml 2131 2139 2131 2139 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g005">Figure 5</xref>
###xml 2413 2418 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
To ensure that the reporter viruses successfully entered quiescent CD4+ T-cells and to exclude the possibility that the nucleofection prevented the infection of the reporter virus, quiescent CD4+ T-cells were infected with virus and immediately stimulated with PHA/IL2. The marker gene expression was monitored by flow cytometry at 48 hr after stimulation. The stimulation status was monitored by the expression levels of two activation markers, CD25 and CD69. Nucleofection did not affect the expression levels of the activation markers (Figure S2). Similar to the results seen in Figures 3 and 4, we did not detect significant gene expression from the reporter virus in APOBEC3G specific siRNAs nucleofected cells (Figure 5, siA3G240 WT/-, siA3G726/- and siA3G883/-). Upon stimulation by PHA/IL-2, EGFP expression was observed in all nucleofected cells (Figure 5, siA3G240 WT/Stim, siA3G726/Stim and siA3G883/Stim). There was a 2-3 fold difference in EGFP expression between unstimulated control cells (Figure 5, Unstimulated/Stim) and siRNA nucleofected cells (Figure 5, siControl/Stim, siA3G240 WT/Stim, siA3G726/Stim, and siA3G883/Stim). However, there were no obvious differences between the cells nucleofected with siRNAs targeting APOBEC3G (Figure 5, siA3G240 WT/Stim, 3.16%; siA3G726/Stim, 3.67%; and siA3G883/Stim, 5.47%) and the mutant (Figure 5, siA3G240MT/Stim, 5.70%) or control siRNA (siControl/Stim, 4.91%). This result indicated that similar amounts of reporter viruses entered into the quiescent CD4+ T-cells under the five experimental conditions, and none of siRNAs targeting APOBEC3G interfered with the entry of the reporter viruses into quiescent CD4+ T-cells. As described above, the difference in EGFP expression between siRNA nucleofected cells and unstimulated control cells after the stimulation is likely to be caused by the cytotoxic effect of nucleofection. The mortality rate increased when using the combination of nucleofection and post-stimulation (45-50% mortality of siRNA nucleofected cells, compared to 25% in unstimulated control cells). Upon infection with heat inactivated reporter virus (Figure 5, HI), no EGFP expression was observed upon stimulation, indicating that the EGFP signals derived from the infected vectors and were not due to pseudo-infection or auto-fluorescence from the cells. Thus, the knock-down of APOBEC3G by siRNA does not affect the efficiency of HIV-1 entry in quiescent CD4+ T-cells.
###end p 28
###begin title 29
###xml 78 83 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Knock-down of APOBEC3G does not affect the levels of reverse transcription in HIV-1-infected quiescent CD4+ T-cells
###end title 29
###begin p 30
###xml 274 277 274 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zack1">[5]</xref>
###xml 278 282 278 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Vatakis1">[10]</xref>
###xml 548 552 548 552 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Vatakis1">[10]</xref>
###xml 890 898 890 898 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g006">Figure 6</xref>
###xml 905 911 905 911 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 918 921 918 921 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 932 935 932 935 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 956 964 956 964 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g006">Figure 6</xref>
###xml 1150 1158 1144 1152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g006">Figure 6</xref>
###xml 1353 1361 1347 1355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000342-g006">Figure 6</xref>
###xml 1923 1927 1917 1921 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 165 170 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 453 458 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 2044 2049 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 can enter into quiescent CD4+ T-cells, but it remains in an inactive state before completion of reverse transcription. Upon subsequent mitogentic stimulation, HIV-1 completes reverse transcription and p24 Gag expression is observable after approximately a 48 hr delay [5],[10]. Chiu et al. reported that this restriction on reverse transcription in quiescent CD4+ T-cells was alleviated by knock-down of APOBEC3G. We lastly examined the status of HIV-1 reverse transcription following downregulation of APOBEC3G. As reported by Vatakis et al.[10], the levels of early reverse transcripts decreased in stimulated cells over time, whereas they hardly changed in unstimulated cells until 48 hr after the reporter virus infection. Similar levels of early reverse transcripts were detected 12 hr after infection and there were no significant differences between siRNAs targeting APOBEC3G (Figure 6, siA3G240 WT, siA3G726, and siA3G883) and control siRNA (Figure 6, siControl) nucleofected cells. Heat inactivation of the reporter viruses for 15 min at 60degreesC decreased the amount of both early and late reverse transcripts to background levels (Figure 6, HI). The levels of reverse transcription in cells nucleofected with either siRNA targeting APOBEC3G, the mutant, or control siRNA were 2-fold lower than that in the unstimulated control cells (Figure 6, unstimulated). This difference may be caused by the cytotoxic effect of nucleofection as described above; the mortality rate in this experiment was 26-32% in siRNA nucleofected cells 48 hr after nucleofection. In contrast, it was 19% in untreated control cells at the same time point. Comparable results were also observed when we measured late reverse transcripts. The levels of late reverse transcripts increased over time, but the levels were similar or slightly lower than those in unstimulated control cells and, in contrast to the results of Chiu et al. [15], never reached the levels observed in stimulated cells. Equivalent results were obtained when replication competent HIV-1 NL4-3 was used for the infection instead of the reporter virus (data not shown). The above results clearly indicated that the knock-down of APOBEC3G by siRNA affected neither the efficiency of initiation of reverse transcription nor the subsequent elongation of cDNA in quiescent CD4+ T-cells.
###end p 30
###begin title 31
Knock-down of APOBE3G does not affect the levels of reverse transcription in the reporter virus-infected quiescent CD4+ T-cells.
###end title 31
###begin p 32
###xml 212 213 212 213 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for two days. Cells were then infected with DNase I-treated VSV-G pseudotyped NL4-3 EGFP reporter virus (125 ng of p24 per 1x105 cells) for 3 hr. Total cellular DNA was isolated at the indicated times and used as a template in quantitative real-time PCR reactions detecting early and late reverse transcripts. Heat-inactivated (HI) viruses were used as negative controls for virus infection. The data represent means+/-standard deviations calculated from triplicate measurements. Comparable results were obtained from three independent experiments. Mock: untreated control.
###end p 32
###begin title 33
Discussion
###end title 33
###begin p 34
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Ganesh1">[14]</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 298 301 298 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Korin2">[9]</xref>
###xml 396 400 396 400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Chiu1">[15]</xref>
###xml 46 51 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 282 287 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 492 497 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 534 539 <span type="species:ncbi:9606">human</span>
###xml 727 732 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The mechanisms involved in the restriction of HIV-1 infection in quiescent CD4+ T-cells remain unidentified. Some potential mechanisms for this blockage may be the presence of cellular inhibitors in quiescent cells [14],[15], the lack of cellular factors required for completion of HIV-1 infection [9] or both. Chiu et al. provided one possible mechanism for the restriction in quiescent T cells [15]. In contrast to their study, our results do not support a role for APOBEC3G in restricting HIV-1 infection of quiescent unstimulated human CD4+ T-cells. We also tested two additional siRNAs that were more efficient at decreasing APOBEC3G, both at the level of mRNA and protein. None of the siRNAs tested resulted in efficient HIV-1 reporter virus infection of quiescent CD4+ T-cells.
###end p 34
###begin p 35
###xml 240 243 240 243 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zack1">[5]</xref>
###xml 1715 1718 1715 1718 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Unutmaz1">[6]</xref>
###xml 1719 1722 1719 1722 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Korin1">[8]</xref>
###xml 1723 1726 1723 1726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Korin2">[9]</xref>
###xml 224 229 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 666 671 <span type="species:ncbi:9606">human</span>
###xml 869 874 <span type="species:ncbi:9606">human</span>
It is unclear to us why our results are discrepant with those of Chiu et al. Our experimental conditions for maintaining quiescent T-cells are that which we used previously including in our first description of the block to HIV-1 infection [5]. From our past experience in working with quiescent T-cells, several factors may influence their behavior, including the source of cells and culture conditions. Our cells are obtained from fresh leukopaks from the UCLA blood bank and processed for peripheral blood mononuclear cell (PBMC) by a Ficoll-Hypaque density gradient within 24 hours. The cells are then used within 0.5 hours. In the past we used selected lots of human AB serum monitored for absence of growth stimulating activity rather than FCS. However, if carefully screened, FCS is also satisfactory and we observed no difference between use of 10% FCS and 10% human AB serum in our results (data not shown). Chiu et al. used 10% FCS for the culture of quiescent CD4+ T-cells. We also considered whether the nucleofection method might affect the results, in particular, the cytotoxicity associated with the procedure. Even under optimized conditions, the nucleofected cells consistently contained around 20% dead cells monitored by forward and side scatter compared to untreated control cells 48 hr after nucleofection. Those dead cells might have caused undesired activation of the remaining cells. We monitored the activation status of the nucleofected cells by CD25 and CD69 staining 48 hr after nucleofection, and as Chiu et al. also reported, we did not observe any induction of CD25 and CD69 expression. However, the activation state of T-cell permissive for infection varies depending on the stimuli [6],[8],[9]. Although the conditions reported by Chiu et al., to culture quiescent cells appear to be the same as ours, it is possible that unknown differences in culture conditions may result in subtle differences in cell activation, giving divergent results.
###end p 35
###begin p 36
###xml 22 27 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 209 214 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 357 362 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Chiu et al. monitored HIV-1 entry and expression using flow cytometric analysis of HSA reporter gene expression. To exclude any confounding effects of marker gene expression or detection methods, we monitored HIV-1 entry by EGFP expression in addition to HSA expression. However, both detection methods showed identical results - we found no enhancement of HIV-1 entry by knocking-down of APOBEC3G in quiescent CD4+ T-cells.
###end p 36
###begin p 37
###xml 272 277 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
In conclusion, we performed all our experiments under previously utilized optimum culture conditions to maintain quiescent T-cells and with experimental manipulation identical to Chiu et al., yet, we could not reproduce their results. As such, we believe the mechanism of HIV-1 restriction for quiescent CD4+ T-cells remains to be elucidated.
###end p 37
###begin title 38
Materials and Methods
###end title 38
###begin title 39
Antibodies
###end title 39
###begin p 40
###xml 19 24 <span type="species:ncbi:10090">mouse</span>
###xml 57 62 <span type="species:ncbi:9606">human</span>
###xml 91 96 <span type="species:ncbi:9606">human</span>
###xml 293 296 <span type="species:ncbi:9685">Cat</span>
PE conjugated anti-mouse CD24, Tri-color conjugated anti-human CD25 and PE conjugated anti-human CD69 monoclonal antibodies and isotype controls were purchased from BD Biosciences (San Jose, CA). Anti-APOBEC3G antibody was obtained from the AIDS Research and Reference Reagent Program at NIH (Cat. No. 10201).
###end p 40
###begin title 41
Primary CD4+ T-cells
###end title 41
###begin p 42
###xml 34 39 <span type="species:ncbi:9606">human</span>
###xml 234 239 <span type="species:ncbi:9606">human</span>
Quiescent CD4+ T-cells from fresh human PBMCs were isolated with CD4+ microbeads (Miltenyi Biotec Inc., Auburn, CA) and maintained in hTC medium (Lonza, Rockland, ME) supplemented with 2 mM L-Glutamine and 10% heat-inactivated FCS or human AB serum. For stimulation, isolated CD4+ T-cells were incubated with PHA (Sigma-Aldrich, St. Louis, MO, 5 microg/ml; ) and IL-2 (Roche Diagnostics, Indianapolis, IN, 20 U/ml) for 36 hr followed by IL-2 (20 U/ml) for 12 hr.
###end p 42
###begin title 43
Nucleofection of siRNA
###end title 43
###begin p 44
###xml 209 210 205 206 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 357 363 353 359 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">240 WT</sub>
###xml 413 416 409 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">726</sub>
###xml 466 469 462 465 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">883</sub>
###xml 837 841 833 837 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Parks1">[29]</xref>
###xml 152 157 <span type="species:ncbi:9606">human</span>
Isolated CD4+ T-cells were transfected with siRNAs using an Amaxa nucleofector (program V-024 as recommended by the manufacturer's protocol for primary human unstimulated T-cells; 2 microg of siRNA per 5-10x106 cells). siRNAs targeting APOBEC3G messenger RNA (Genebank accession number: NM_021822) at residues 240-258 in cording sequence for APOBEC3G (siA3G240 WT), 726-746 in cording sequence for APOBEC3G (siA3G726), 883-901 in cording sequence for APOBEC3G (siA3G883) were chemically synthesized by Qiagen (Chatsworth, CA) or Dharmacon (Chicago, IL). siRNA targeting CD4 (siCD4: #1024675) and control siRNA (siControl: #1027310) were purchased from Qiagen. Since dead cells have lower-forward scatter and higher-side scatter than live cells, cytotoxicity by nucleofection was monitored by measuring the dead cells with flow cytometry [29].
###end p 44
###begin title 45
Virus production and titration
###end title 45
###begin p 46
###xml 111 115 111 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-He1">[27]</xref>
###xml 338 342 334 338 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Kamata1">[30]</xref>
###xml 47 52 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
We generated lentiviral vector stocks using an HIV-1 based reporter virus encoding HSA or EGFP (NL4-3 HSA R-E- [27] or NL4-3 EGFP R-E- substituted HSA with EGFP, respectively), packaging plasmid pCMV R8.2 deltaVpr, and the VSV-G envelope protein-coding plasmid by calcium phosphate-mediated transient transfection as previously described [30]. After 48 and 72 hr, lentiviral vector particles were harvested and concentrated by ultracentrifugation through a 10% sucrose cushion in Hanks' balanced salt solution (HBSS) with 1 mM EDTA and resuspended in a 100-fold lower volume of HBSS and stored at -80degreesC. The viral titer was measured by anti-p24 Gag ELISA and the infectious titer was determined in 293T cells by infecting with HSA or EGFP encoding vector and flow cytometric analysis.
###end p 46
###begin title 47
Viral infection and detection
###end title 47
###begin p 48
###xml 107 108 107 108 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Forty-eight hr after nucleofection, CD4+ T-cells were incubated with reporter virus (125 ng of p24 per 1x105 cells) with 8 microg/ml of polybrene. After 3 hr incubation at 37degreesC, cells were washed extensively with phosphate buffered saline (PBS) and cultured for 48 hr in the presence or absence of 25 microM AZT (A2169; Sigma-Aldrich). Unstimulated and non-nucleofected cells served as negative controls. Reporter gene expression (HSA and EGFP) and the activation markers (CD25 and CD69) were monitored by flow cytometry. Data were collected on a Cytomics FC500 (Beckman Coulter, Fullerton, CA) and analyzed using FCS express (De Novo Software, Los Angeles, CA).
###end p 48
###begin title 49
Real-time PCR
###end title 49
###begin p 50
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 497 521 494 518 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CGCAGCCTGTGTCAGAAAAG3&#8242;</named-content>
###xml 532 560 529 557 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CCAACAGTGCTGAAATTCGTCATA3&#8242;</named-content>
###xml 569 597 566 594 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">FAM-5&#8242;GTGCCACCATGAAGA3&#8242;-BHQ1</named-content>
###xml 597 601 594 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Jin1">[31]</xref>
###xml 623 645 617 639 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;CGAGCGCGGCTACAGCTT3&#8242;</named-content>
###xml 656 681 650 675 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242; CCTTAATGTCACGCACGATT3&#8242;</named-content>
###xml 690 721 684 715 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">HEX-5&#8242;ACCACCACGGCCGAGCGG3&#8242;-BHQ2</named-content>
All real-Time PCR quantitations were performed using the BIO-RAD iQ5 system (BioRad, Hercules, CA) in parallel with a set of known quantitative standards. For quantitation of APOBEC3G mRNA, total RNA was extracted from approximately 5x105 cells with TRIZOL and used for quantitative real-time RT-PCR. The iScript one-step RT-PCR kit for probes (BioRad) was used with a 40 ng of total RNA for amplification of APOBEC3G and beta-actin as control. The primers used were as follows. APOBEC3G: forward 5'CGCAGCCTGTGTCAGAAAAG3'; reverse, 5'CCAACAGTGCTGAAATTCGTCATA3'; probe, FAM-5'GTGCCACCATGAAGA3'-BHQ1[31]. beta-actin: forward 5'CGAGCGCGGCTACAGCTT3'; reverse, 5' CCTTAATGTCACGCACGATT3'; probe, HEX-5'ACCACCACGGCCGAGCGG3'-BHQ2. All primers and probe were synthesized by Biosearch Technologies Inc. (Novato, CA). All RT-PCR reactions were carried out as follows: reverse transcription at 50degreesC for 10 min, inactivation of reverse transcriptase at 95degreesC for 5 min, and subsequently 45 cycles in two phases consisting of 95degreesC for 15 sec, and 58degreesC for 30 sec. APOBEC3G mRNA was normalized using the endogenous beta-actin mRNA as a reference.
###end p 50
###begin p 51
###xml 140 143 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zack1">[5]</xref>
###xml 144 147 144 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Korin1">[8]</xref>
###xml 199 200 199 200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 528 531 528 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Zack1">[5]</xref>
###xml 44 49 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 488 493 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 663 668 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 721 724 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Virus infection was measured by quantifying HIV-1 early and late reverse transcripts using TaqMan real-time DNA PCR as previously described [5],[8]. Briefly, DNA was extracted from approximately 5x105 cells with urea lysis buffer [4.7 M urea, 1.3% W/V SDS, 0.23 M NaCl, 0.67 mM EDTA, and 6.7 mM Tris-HCl (pH 8.0)] and then subjected to phenol-chloroform extraction and ethanol precipitation. Quantitative real-time DNA PCR was performed by iQ Supermix (BioRad) using primers specific for HIV-1 sequences as previously described [5]. The primer pairs M667/AA55 (R/U5 region) and M667/M661 (LTR/gag region) were used to detect early and late reverse transcripts of HIV-1, respectively. The standard curve used to determine HIV-DNA levels range from 1-1,000,000 copies of NL4-3 DNA. There was no background contamination from DNA of mock infected cells. The amounts of early and late reverse transcripts were normalized using the endogenous beta-globin gene as a reference.
###end p 51
###begin title 52
Western blotting for APOBEC3G proteins
###end title 52
###begin p 53
###xml 4 5 4 5 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 212 216 212 216 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000342-Kamata1">[30]</xref>
###xml 510 513 <span type="species:ncbi:9685">Cat</span>
###xml 751 762 <span type="species:ncbi:3704">horseradish</span>
1x106 cells were lysed with 0.5% SDS containing protease inhibitor cocktail (P8340; Sigma-Aldrich) and quantified with a BCA protein assay reagent (BioRad). Western blotting was performed as described previously [30]. Briefly, 2.5 microg protein was electrophoresis on 4-20% Precast SDS-PAGE gel (Lonza) and transferred onto immobilon membranes (Millipore, Bedford, MA). After blocking with 5% skim milk in PBS with 0.05% Tween-20 (PBS-T), membranes were reacted with either polyclonal anti-APOBEC3G antibody (Cat. No. 10201, NIH AIDS Research and Reference Reagent Program) or polyclonal anti-beta-Actin (Rockland Immunochemicals Inc., Gilbertsville, PA). Membranes were washed with PBS-T three times, treated with secondary antibody conjugated with horseradish peroxidase (Pierce, Rockford, IL) and visualized by chemiluminescence (ECL plus; Amersham Biosciences, Piscataway, NJ).
###end p 53
###begin title 54
Supporting Information
###end title 54
###begin p 55
###xml 405 406 405 406 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
###xml 19 24 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The infectivity of HIV-1 reporter virus on APOBEC3G knocked-down quiescent CD4+ T-cells is not affected by virus multiplicity of infection. Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for three days (A) or four days (B). Cells were subsequently infected with VSV-G pseudotyped NL4-3 EGFP reporter virus at three different MOIs (125, 250, and 500 ng of p24 per 1x105 cells) for 3 hr, and cultured in the absence or presence of 25 microM AZT. Expression of EGFP was monitored 48 hr after infection by flow cytometry. Unstimulated non-nucleofected cells (Unstimulated) and unstimulated cells nucleofected with control siRNA (siControl) or buffer only (buffer) served as negative controls. Cells stimulated with PHA (5 microg/ml) and IL-2 (20 U/ml) served as positive controls (Stimulated). Comparable results were obtained using cells from two different donors.
###end p 55
###begin p 56
(5.56 MB TIF)
###end p 56
###begin p 57
Click here for additional data file.
###end p 57
###begin p 58
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5</sup>
Knock-down of APOBEC3G does not affect the activation status of quiescent CD4+ T-cells. Quiescent CD4+ T-cells derived from PBMCs were nucleofected with siRNAs and cultured for two days. Cells were then infected with VSV-G pseudotyped NL4-3 EGFP reporter virus (125 ng of p24 per 1x105 cells) for 3 hr. After infection, half of cells were stimulated with PHA (5 microg/ml) and IL-2 (20 U/ml) (Stim), and the other half of the cells were cultured without stimulation (-). The levels of CD25 and CD69 were monitored two days after infection by flow cytometry. Unstimulated none-nucleofected cells (Unstimulated), and unstimulated cell nucleofected with control siRNA (siControl) served as negative controls. Cells stimulated with PHA (5 microg/ml) and IL-2 (20 U/ml) served as positive controls (Stimulated). Comparable results were obtained using cells from three different donors. Heat-inactivated (HI) viruses were used as negative controls for virus infection.
###end p 58
###begin p 59
(6.41 MB TIF)
###end p 59
###begin p 60
Click here for additional data file.
###end p 60
###begin p 61
We are grateful to Dr. Betty Poon for proofreading the manuscript and to Si-Hua Mao for technical help. We thank Drs. Jerome A. Zack and Dimitrios N. Vatakis for great technical assistance and for critical reading of the manuscript. The following reagents were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH: Anti-APOBEC3G-C terminal antibody from Dr. Jaisri Lingappa, pNL4-3.HSA.R-E- from Dr. Nathaniel Landau.
###end p 61
###begin title 62
References
###end title 62
###begin article-title 63
###xml 12 47 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Kinetics of human immunodeficiency virus type 1 decay following entry into resting CD4+ T cells.
###end article-title 63
###begin article-title 64
###xml 5 8 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Long HIV type 1 reverse transcripts can accumulate stably within resting CD4+ T cells while short ones are degraded.
###end article-title 64
###begin article-title 65
###xml 56 91 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.
###end article-title 65
###begin article-title 66
###xml 26 31 <span type="species:ncbi:9606">human</span>
###xml 80 108 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Highly purified quiescent human peripheral blood CD4+ T cells are infectible by human immunodeficiency virus but do not release virus after activation.
###end article-title 66
###begin article-title 67
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure.
###end article-title 67
###begin article-title 68
###xml 36 41 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
###xml 63 68 <span type="species:ncbi:9606">human</span>
Cytokine signals are sufficient for HIV-1 infection of resting human T lymphocytes.
###end article-title 68
###begin article-title 69
Subcompartments of the G1 phase of cell cycle detected by flow cytometry.
###end article-title 69
###begin article-title 70
###xml 77 112 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Progression to the G1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells.
###end article-title 70
###begin article-title 71
###xml 14 49 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Nonproductive human immunodeficiency virus type 1 infection in nucleoside-treated G0 lymphocytes.
###end article-title 71
###begin article-title 72
###xml 47 75 <span type="species:ncbi:12721">human immunodeficiency virus</span>
Immediate activation fails to rescue efficient human immunodeficiency virus replication in quiescent CD4+ T cells.
###end article-title 72
###begin article-title 73
###xml 33 68 <span type="species:ncbi:11676">human immunodeficiency virus type 1</span>
Incompletely reverse-transcribed human immunodeficiency virus type 1 genomes in quiescent cells can function as intermediates in the retroviral life cycle.
###end article-title 73
###begin article-title 74
Retroviral infection of non-dividing cells: old and new perspectives.
###end article-title 74
###begin article-title 75
Retrovirus restriction factors.
###end article-title 75
###begin article-title 76
###xml 33 38 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes.
###end article-title 76
###begin article-title 77
###xml 28 33 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
###end article-title 77
###begin article-title 78
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif, APOBEC, and intrinsic immunity.
###end article-title 78
###begin article-title 79
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 52 55 <span type="species:ncbi:12721?0.9873544761140104">HIV</span>
Human APOBEC3 proteins, retrovirus restriction, and HIV drug resistance.
###end article-title 79
###begin article-title 80
###xml 32 37 <span type="species:ncbi:9606">human</span>
Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
###end article-title 80
###begin article-title 81
###xml 15 20 <span type="species:ncbi:9606">human</span>
###xml 40 45 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.
###end article-title 81
###begin article-title 82
###xml 72 77 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA.
###end article-title 82
###begin article-title 83
The APOBEC3 cytidine deaminases: an innate defensive network opposing exogenous retroviruses and endogenous retroelements.
###end article-title 83
###begin article-title 84
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation.
###end article-title 84
###begin article-title 85
###xml 80 85 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif.
###end article-title 85
###begin article-title 86
###xml 0 5 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability.
###end article-title 86
###begin article-title 87
The intrinsic antiretroviral factor APOBEC3B contains two enzymatically active cytidine deaminase domains.
###end article-title 87
###begin article-title 88
###xml 38 55 <span type="species:ncbi:10407">hepatitis B virus</span>
Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G.
###end article-title 88
###begin article-title 89
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity.
###end article-title 89
###begin article-title 90
###xml 81 86 <span type="species:ncbi:11676?0.8769782024484921">HIV-1</span>
APOBEC3G/3F mediates intrinsic resistance of monocyte-derived dendritic cells to HIV-1 infection.
###end article-title 90
###begin article-title 91
Fluorescence-activated cell sorting: theory, experimental optimization, and applications in lymphoid cell biology.
###end article-title 91
###begin article-title 92
###xml 0 35 <span type="species:ncbi:11676">Human immunodeficiency virus type 1</span>
Human immunodeficiency virus type 1 Vpr binds to the N lobe of the Wee1 kinase domain and enhances kinase activity for CDC2.
###end article-title 92
###begin article-title 93
###xml 59 87 <span type="species:ncbi:12721">human immunodeficiency virus</span>
APOBEC3G/CEM15 (hA3G) mRNA levels associate inversely with human immunodeficiency virus viremia.
###end article-title 93
###begin p 94
The authors have declared that no competing interests exist.
###end p 94
###begin p 95
This work was supported by the NIH grant A1028697 (UCLA CFAR, ). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 95

